Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery Invests in New Technologies with £190K N2 Business Growth Fund Grant

Sygnature Discovery is set for further growth after receiving a £190,000 grant from the N2 Business Growth Fund.

Sygnature, which employs over 150 staff and already has 8 laboratories in its existing facilities in BioCity Nottingham, is set to expand further by taking space in the new £30m Discovery Building from March 2017.  The company will use the N2 grant money to buy new laboratory equipment to support its plans to increase its Nottingham-based workforce by 30 percent.

The university administered fund is designed to help businesses exploit new technologies and invest in capital projects.  It offers grants of up to 20 percent of innovation project costs.  Speaking about the grant, Mrs Victoria Tabiner, Sygnature Discovery’s Finance Director, emphasised the importance of the N2 grant.  She said, “Sygnature is delighted to have secured recent investment from the N2 Business Growth Fund.  We have already ordered new laboratory equipment with the support of the grant, which will allow us to further our drug research capabilities on our Nottingham site.”

Grants ranging from £20,000 up to £250,000 are available for local businesses that want to invest in capital or equipment, or that want to exploit intellectual property and new technologies.  Grants worth more than £1.1m have already been made to businesses in Nottinghamshire, which is expected to create 140 new jobs.

Latest News

View All

Sygnature Discovery and UBE Corporation successfully identify…

Sygnature Discovery’s hit finding expertise in high…

Sygnature Discovery accelerates global growth with major…

Sygnature Discovery launches its in vivo LPS…